EP1943350A4 - Latent procytotoxins and uses thereof - Google Patents

Latent procytotoxins and uses thereof

Info

Publication number
EP1943350A4
EP1943350A4 EP06825387A EP06825387A EP1943350A4 EP 1943350 A4 EP1943350 A4 EP 1943350A4 EP 06825387 A EP06825387 A EP 06825387A EP 06825387 A EP06825387 A EP 06825387A EP 1943350 A4 EP1943350 A4 EP 1943350A4
Authority
EP
European Patent Office
Prior art keywords
procytotoxins
latent
latent procytotoxins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06825387A
Other languages
German (de)
French (fr)
Other versions
EP1943350A2 (en
Inventor
Thomas E Wagner
Xianzhang Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Greenville Hospital System
Original Assignee
Greenville Hospital System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greenville Hospital System filed Critical Greenville Hospital System
Publication of EP1943350A2 publication Critical patent/EP1943350A2/en
Publication of EP1943350A4 publication Critical patent/EP1943350A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP06825387A 2005-10-04 2006-09-29 Latent procytotoxins and uses thereof Withdrawn EP1943350A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72351105P 2005-10-04 2005-10-04
PCT/US2006/038584 WO2007044321A2 (en) 2005-10-04 2006-09-29 Latent procytotoxins and uses thereof

Publications (2)

Publication Number Publication Date
EP1943350A2 EP1943350A2 (en) 2008-07-16
EP1943350A4 true EP1943350A4 (en) 2009-06-17

Family

ID=37943314

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06825387A Withdrawn EP1943350A4 (en) 2005-10-04 2006-09-29 Latent procytotoxins and uses thereof

Country Status (5)

Country Link
EP (1) EP1943350A4 (en)
JP (1) JP2009510166A (en)
AU (1) AU2006302587A1 (en)
CA (1) CA2624802A1 (en)
WO (1) WO2007044321A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004694A1 (en) * 2012-06-26 2014-01-03 Massachusetts Institute Of Technology Reversible masking of pore-forming proteins for macromolecular delivery
CN103275911B (en) * 2013-01-02 2015-11-25 温州医学院 A kind of intestinal bacteria containing pET-28a (+)-protein400 recombinant plasmid and preparation method thereof
US9950030B2 (en) * 2013-06-27 2018-04-24 Rutgers, The State University Of New Jersey Treatment and diagnosis of ocular disease
CN106632633B (en) * 2016-11-24 2020-03-20 浙江海洋大学 Abelmoschus moschatus antitumor oligopeptide and application thereof
US20240082350A1 (en) * 2019-10-11 2024-03-14 Linnane Pharma Ab Vibrio cholerae protein for use against cancer
CN112724258A (en) * 2019-10-29 2021-04-30 深圳市第二人民医院 Composite polypeptide molecule for targeted killing of cancer cells and preparation method thereof
CA3189545A1 (en) * 2020-07-17 2022-01-20 The University Of Western Australia Compositions and methods for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020045736A1 (en) * 2001-05-09 2002-04-18 Xianxhang Yu Lytic peptide prodrugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6942853B2 (en) * 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020045736A1 (en) * 2001-05-09 2002-04-18 Xianxhang Yu Lytic peptide prodrugs

Also Published As

Publication number Publication date
WO2007044321A2 (en) 2007-04-19
JP2009510166A (en) 2009-03-12
AU2006302587A1 (en) 2007-04-19
WO2007044321A3 (en) 2007-07-05
EP1943350A2 (en) 2008-07-16
CA2624802A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
IL222922A (en) Anti-neuropilin-1 antibodies and uses thereof
EP1802588A4 (en) Substituted amino-pyrimidones and uses thereof
HK1119441A1 (en) Toner
GB0512940D0 (en) Compounds and their use
AP2008004471A0 (en) Anti-Alpha2 Intergin antibodies and their uses
EP1944655A4 (en) Toner
IL184024A0 (en) Irta-5 antibodies and their uses
IL189609A0 (en) 4-substituted pyrrolidin-2-ones and their use
EP1962142A4 (en) Toner
IL179497A0 (en) Carboranylporphyrins and uses thereof
GB0520743D0 (en) Compounds and their use
EP1893569A4 (en) Sulfonamide compounds and uses thereof
IL189252A0 (en) Dihydroxyanthraquinones and their use
HK1133552A1 (en) Carboranylporphyrins and uses thereof
EP1912921A4 (en) Tetraazaporphyrin-based compounds and their uses
GB0502979D0 (en) Biomarkers and uses thereof
EP1921066A4 (en) Pyridylphenol compound and use thereof
IL185223A0 (en) Compounds and uses thereof
IL180365A0 (en) Carboranylporphyrins and uses thereof
EP1943350A4 (en) Latent procytotoxins and uses thereof
EP1887432A4 (en) Toner and toner binder
GB0520935D0 (en) Integrated processor-template-system and project
GB0502978D0 (en) Biomarkers and uses thereof
GB0517239D0 (en) Geogrotren-mk1-system and project
GB0517240D0 (en) Chronorotron mk1-system and project

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080408

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20090520

17Q First examination report despatched

Effective date: 20090907

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100318